Paris, France-based Kurma Partners has held the first closing of its third venture capital fund at €33m.
Backed by The European Investment Fund, Fonds National d’Amorçage, Institut Pasteur and BNP Paribas, Kurma Diagnostics is a venture accelerator fund that finances early-stage European innovative Diagnostic projects and companies.
The fund will look at the full scope of diagnostic opportunities; from imaging systems, software, sample collection and management, biomarkers all the way through to platform technologies and e-health systems.
It will seed projects at pre-industrialization stage within a 12-24 month period, and incorporate them into a specifically designed accelerator during this early phase.
Founded in July 2009, Kurma has made investments across Europe via two funds, in therapeutics, devices, and diagnostics companies: Kurma Biofund I (€51M) & Kurma Biofund II (€75M).
FinSMEs
26/05/2015